US 10434100
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
granted A61KA61K31/34A61K31/454
Quick answer
US patent 10434100 (Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes) held by Lixte Biotechnology, Inc. expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Lixte Biotechnology, Inc.
- Grant date
- Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K31/454, A61K31/496, A61K31/573